Chemosensitivity testing in ovarian cancer
β Scribed by Bernd-Uwe Sevin; James P. Perras; Hervy E. Averette; Daniel M. Donato; Manuel Penalver
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 781 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Although p53 gene mutation frequently is observed in ovarian carcinoma, the function of the p53 gene in chemosensitivity has not been defined conclusively. The objective of the current study was to elucidate the relation between chemotherapy-induced apoptosis through the p53 pathway
It has been shown that women who have taken the oral contraceptive pill for 4 or 5 years decreases the incidence of ovarian cancer by approximately 40%. It is estimated that the oral contraceptive pill can prevent approximately 1500 ovarian cancers each year. The postmenopausal palpable ovary syndr
## Abstract Cysteamine (CS) has many biomedical and clinical applicationsΒ because ofΒ its excellent water solubility, low cytotoxicity and good biocompatibility. A previousΒ study by Brawer et al. reported the occurrence of many Gomori inclusion bodies in CSβtreated astrocytes, which would suggest th